An update on epidermal growth factor receptor inhibitors.

被引：23

作者：

Modi S. ^{[1
]}

Seidman A.D. ^{[1
]}

机构：

[1] Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, 10021, NY

来源：

Current Oncology Reports | 2002年 / 4卷 / 1期

关键词：

Epidermal Growth Factor Receptor; Ovarian Cancer Cell; Epidermal Growth Factor Receptor Tyrosine Kinase; Human Tumor Xenograft; Epidermal Growth Factor Receptor Activation;

D O I：

10.1007/s11912-002-0047-6

中图分类号：

学科分类号：

摘要：

The epidermal growth factor receptor (EGFR) is part of a family of plasma membrane receptor tyrosine kinases that control many important cellular functions, from cell growth and proliferation to cell death. Dysregulation of the EGFR signal transduction pathway has been implicated in tumorigenesis and cancer progression, making it a clinically relevant target for novel anticancer treatments. This paper reviews recent progress in the development of cancer therapies that are directed toward particular aspects of the extracellular and intracellular domains of EGFR. Promising new compounds in the advanced stages of clinical testing are emphasized.

引用

页码：47 / 55

页数：8

共 152 条

[31]

Hong WK(1996)Why toxins Semin Cancer Biol 7 87-95

[32]

Arquette M(2000)Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regressions in vivo Int J Cancer 86 269-275

[33]

Nabell L(1999)Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1 Clin Cancer Res 5 2646-2652

[34]

Saltz L(1996)Targeted inhibition of tumor cell growth by a bispecific single-chain toxin containing an antibody domain and TGF alpha Br J Cancer 74 853-862

[35]

Rubin M(1995)Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancer Clin Cancer Res 1 57-61

[36]

Hochster H(1995)Diphtheria toxin-based receptor-specific chimaeric toxins as targeted therapy Essays Biochem 30 119-131

[37]

Abbruzzese JL(2000)New therapeutic agents targeting the epidermal growth factor receptor J Clin Oncol 18 54s-59s

[38]

Rosenberg A(1998)Phase I data of ZD1839—an oral epidermal growth factor receptor tyrosine kinase inhibitor [abstract] Ann Oncol 9 109-109

[39]

Xiong Q(2000)Intermittent oral ZD 1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor, shows evidence of good tolerability and activity: final results from a phase I study [abstract] Proc ASCO 19 3a-3a

[40]

Ye D(2000)Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD 1839 (Iressa), an inhibitor of EGFR tyrosine kinase Clin Cancer Res 6 4885-4892

← 1 2 3 4 5 6 7 8 9 10 →